GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (WBO:DIAS) » Definitions » Gross Profit

Diasorin SpA (WBO:DIAS) Gross Profit : €773 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Diasorin SpA Gross Profit?

Diasorin SpA's gross profit for the three months ended in Jun. 2024 was €198 Mil. Diasorin SpA's gross profit for the trailing twelve months (TTM) ended in Jun. 2024 was €773 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Diasorin SpA's gross profit for the three months ended in Jun. 2024 was €198 Mil. Diasorin SpA's Revenue for the three months ended in Jun. 2024 was €300 Mil. Therefore, Diasorin SpA's Gross Margin % for the quarter that ended in Jun. 2024 was 66.00%.

Diasorin SpA had a gross margin of 66.00% for the quarter that ended in Jun. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Diasorin SpA was 69.19%. The lowest was 64.55%. And the median was 67.93%.

Warning Sign:

Diasorin SpA gross margin has been in long-term decline. The average rate of decline per year is -1.2%.


Diasorin SpA Gross Profit Historical Data

The historical data trend for Diasorin SpA's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA Gross Profit Chart

Diasorin SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 488.69 602.91 824.77 900.61 741.19

Diasorin SpA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 167.00 195.19 192.00 198.00 188.00

Competitive Comparison of Diasorin SpA's Gross Profit

For the Diagnostics & Research subindustry, Diasorin SpA's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diasorin SpA's Gross Profit Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Gross Profit distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's Gross Profit falls into.



Diasorin SpA Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Diasorin SpA's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=1148.21 - 407.024
=741

Diasorin SpA's Gross Profit for the quarter that ended in Jun. 2024 is calculated as

Gross Profit (Q: Jun. 2024 )=Revenue - Cost of Goods Sold
=300 - 102
=198

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €773 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Diasorin SpA's Gross Margin % for the quarter that ended in Jun. 2024 is calculated as

Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=198 / 300
=66.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Diasorin SpA  (WBO:DIAS) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Diasorin SpA had a gross margin of 66.00% for the quarter that ended in Jun. 2024 => Durable competitive advantage


Diasorin SpA Gross Profit Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Diasorin SpA Business Description

Traded in Other Exchanges
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).

Diasorin SpA Headlines

No Headlines